7JN logo

Poolbeg Pharma DB:7JN Stock Report

Last Price

€0.14

Market Cap

€74.9m

7D

-6.7%

1Y

90.5%

Updated

23 Jul, 2024

Data

Company Financials +

7JN Stock Overview

Operates as a biopharmaceutical company, engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom.

7JN fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Poolbeg Pharma PLC Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Poolbeg Pharma
Historical stock prices
Current Share PriceUK£0.14
52 Week HighUK£0.17
52 Week LowUK£0.065
Beta2.19
11 Month Change2.94%
3 Month Change25.00%
1 Year Change90.48%
33 Year Change23.89%
5 Year Changen/a
Change since IPO50.86%

Recent News & Updates

Recent updates

Shareholder Returns

7JNDE PharmaceuticalsDE Market
7D-6.7%0.1%-0.9%
1Y90.5%-22.6%1.9%

Return vs Industry: 7JN exceeded the German Pharmaceuticals industry which returned -22.6% over the past year.

Return vs Market: 7JN exceeded the German Market which returned 1.9% over the past year.

Price Volatility

Is 7JN's price volatile compared to industry and market?
7JN volatility
7JN Average Weekly Movement12.0%
Pharmaceuticals Industry Average Movement4.6%
Market Average Movement4.6%
10% most volatile stocks in DE Market10.7%
10% least volatile stocks in DE Market2.5%

Stable Share Price: 7JN's share price has been volatile over the past 3 months.

Volatility Over Time: 7JN's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
202115Jeremy Skillingtonwww.poolbegpharma.com

Poolbeg Pharma PLC operates as a biopharmaceutical company, engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom. It develops POLB 001, which is in phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome and severe influenza. The company is also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; influenza and respiratory syncytial virus AI programme; POLB 002, an in­licensed first­in­class broad spectrum RNA­based immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis.

Poolbeg Pharma PLC Fundamentals Summary

How do Poolbeg Pharma's earnings and revenue compare to its market cap?
7JN fundamental statistics
Market cap€74.92m
Earnings (TTM)-€4.67m
Revenue (TTM)n/a

0.0x

P/S Ratio

-16.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
7JN income statement (TTM)
RevenueUK£0
Cost of RevenueUK£0
Gross ProfitUK£0
Other ExpensesUK£3.93m
Earnings-UK£3.93m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.0079
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did 7JN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.